Clinical Trial Update: Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Angiomax (bivalirudin) in patients with HIT/HITTS type II undergoing off-pump coronary artery bypass grafting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Bypass Surgery
• Coronary Artery Disease
• Thrombocytopenia
• Thrombosis

Drugs mentioned

• Angiomax (bivalirudin)

Snippet

Sponsor: The Medicines Company | Conditions: Thrombocytopenia, Thrombosis | Phase 3 | Status: COMPLETED